Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsLaura Niklason, PhD, MD
Professor AdjunctAbout
Copy Link
Titles
Professor Adjunct
Division Chief; Vice Chair, Research
Biography
Dr. Niklason is the Nicholas M. Greene Professor at Yale University in Anesthesia and Biomedical Engineering, where she has been on faculty since 2006. Dr. Niklason’s research focuses primarily on regenerative strategies for cardiovascular and lung tissues. Niklason’s engineered blood vessels are currently in clinical trials, and are the first life-sustaining engineered tissue to be studied in any Phase III trial. Niklason’s lab was also one of the first to describe the engineering of whole lung tissue that could exchange gas in vivo, and this work was cited in 2010 as one of the top 50 most important inventions of the year by Time Magazine. She was inducted into the National Academy of Inventors in 2014, and was elected to the National Academy of Medicine in 2015.
Niklason received her PhD in Biophysics from the University of Chicago, and her MD from the University of Michigan. She completed her residency training in anesthesia and intensive care unit medicine at the Massachusetts General Hospital in Boston, and completed post-doctoral scientific training at Massachusetts Institute of Technology.
Appointments
Anesthesiology
Professor AdjunctPrimary
Other Departments & Organizations
Education & Training
- Fellow
- Mass General Hospital (1996)
- Resident
- Mass General Hospital (1995)
- Intern
- University of Michigan (1992)
- MD
- University of Michigan/Ann Arbor (1991)
- PhD
- University of Chicago (1988)
Research
Copy Link
Overview
- Tissue engineered arteries, utilizing decellularization approaches
- Regeneration of whole, functional lung tissue
- Engineering of thoracic conduits, including trachea and esophagus
- Investigation of the molecular basis of cellular aging in various tissues
- Investigation of causes of intimal hyperplasia in vein grafts
Medical Research Interests
ORCID
0000-0002-5156-504X
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Liping Zhao, MS, HT (ASCP)
Micha Sam Brickman Raredon, MD, PhD
Allison M. Greaney, PhD
Naftali Kaminski, MD
David J Leffell, MDCM, MD
Dianqing (Dan) Wu, PhD
Tissue Engineering
Lung
Blood Vessels
Publications
2026
Use of the Acellular Tissue Engineered Vessel for Torso Arterial Trauma: Case Reports From the CLN-PRO-V005 Trial
Magee G, Bou-Ghannam S, Berdugo M, Parikh S, Niklason L. Use of the Acellular Tissue Engineered Vessel for Torso Arterial Trauma: Case Reports From the CLN-PRO-V005 Trial. Journal Of Vascular Surgery 2026, 83: s47. DOI: 10.1016/j.jvs.2025.12.254.Peer-Reviewed Original ResearchConceptsClinical Effectiveness of an Acellular Tissue Engineered Vessel: Review of Published Outcomes Across Multiple Vascular Indications
Curi M, Bou-Ghannam S, Parikh S, Niklason L. Clinical Effectiveness of an Acellular Tissue Engineered Vessel: Review of Published Outcomes Across Multiple Vascular Indications. Journal Of Vascular Surgery 2026, 83: s44-s45. DOI: 10.1016/j.jvs.2025.12.248.Peer-Reviewed Original ResearchUse of the Acellular Tissue Engineered Vessel in Distal Revascularization and Interval Ligation Procedures for Dialysis Access-Associated Steal Syndrome: Case Series From the CLN-PRO-V005 Clinical Trial
Moore E, Bou-Ghannam S, Niklason L, Berdugo M, Parikh S. Use of the Acellular Tissue Engineered Vessel in Distal Revascularization and Interval Ligation Procedures for Dialysis Access-Associated Steal Syndrome: Case Series From the CLN-PRO-V005 Clinical Trial. Journal Of Vascular Surgery 2026, 83: s19-s20. DOI: 10.1016/j.jvs.2025.12.201.Peer-Reviewed Original ResearchTwo-year Outcomes in Female Patients From a Prospective Randomized Trial of Humacyte’s Acellular Tissue Engineered Vessel vs Autologous Arteriovenous Fistula for Hemodialysis
Hussain M, Bou-Ghannam S, Bates R, Khondker Z, Berdugo M, Parikh S, Niklason L. Two-year Outcomes in Female Patients From a Prospective Randomized Trial of Humacyte’s Acellular Tissue Engineered Vessel vs Autologous Arteriovenous Fistula for Hemodialysis. Journal Of Vascular Surgery 2026, 83: s19. DOI: 10.1016/j.jvs.2025.12.199.Peer-Reviewed Original ResearchIn Vivo Regeneration of Bioengineered Blood Vessels: Histological Evaluation of Acellular Tissue Engineered Vessels After Long-term Clinical Use
Pascarella L, Kirkton R, Wang J, Levitan G, Niklason L. In Vivo Regeneration of Bioengineered Blood Vessels: Histological Evaluation of Acellular Tissue Engineered Vessels After Long-term Clinical Use. Journal Of Vascular Surgery 2026, 83: s20-s21. DOI: 10.1016/j.jvs.2025.12.203.Peer-Reviewed Original ResearchEngineering function in lung biology: integrating imaging, regenerative constructs, and functional biodesign
Girard R, Tran J, Cai Y, Farach-Carson M, Nia H, Greaney A, Niklason L, Hurley K, Blanco E, Koc-Günel S, Karmouty-Quintana H. Engineering function in lung biology: integrating imaging, regenerative constructs, and functional biodesign. American Journal Of Physiology - Lung Cellular And Molecular Physiology 2026, 330: l653-l660. PMID: 42030197, PMCID: PMC13198914, DOI: 10.1152/ajplung.00066.2026.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAltmetricMeSH Keywords and ConceptsVascular Endothelial Growth Factor-D Improves Lung Vascular Integrity During Acute Lung Injury
Yoon Y, Sharma L, Tang W, Kirk S, Raredon M, Ahangari F, Khoury J, Qian H, Ke Y, Tulapurkar M, Liu R, Luan Y, Yuan Q, Chen L, Birukov K, Simons M, Wu D, Niklason L, Kaminski N, Yuan Y. Vascular Endothelial Growth Factor-D Improves Lung Vascular Integrity During Acute Lung Injury. Circulation Research 2026, 138: e326094. PMID: 41822962, PMCID: PMC13007730, DOI: 10.1161/circresaha.124.326094.Peer-Reviewed Original ResearchCitationsAltmetricConceptsVEGF-DAcute lung injuryBarrier-protective effectsVascular integrityLung injuryLipopolysaccharide-induced acute lung injury modelIntravenous administrationTNF-aParacrine signalingModel of acute lung injuryPulmonary vascular integrityLigand-receptor interactionsImmune cell infiltrationAcute lung injury modelLung vascular integrityVEGFR2-dependent signalingLung injury modelEndothelial barrier integrityEndothelial barrier functionRNA sequencing dataMicrovascular endothelial cellsInhibition of VEGFR2Microvascular nichePharmacological blockadeAssociated with pathwaysReply Model Choice and Interpretation in Coronary Tissue Engineering: Still More Questions Than Answers
Nash K, Kirkton R, Niklason L, Kypson A. Reply Model Choice and Interpretation in Coronary Tissue Engineering: Still More Questions Than Answers. JACC Basic To Translational Science 2026, 11: 101464. PMID: 41589776, PMCID: PMC12902263, DOI: 10.1016/j.jacbts.2025.101464.Commentaries, Editorials and LettersConceptsSingle-cell atlas of human lung aging identifies cell type dyssynchrony and increased transcriptional entropy
De Man R, McDonough J, Adams T, Nikola F, Rangel R, Anderson S, Manning E, Cala Garcia J, Moss B, Waich A, Poli F, Cardenas R, Coarfa C, Song Q, Bar-Joseph Z, Vanaudenaerde B, Wuyts W, Niklason L, Raredon M, Yan X, Rosas I, Kaminski N. Single-cell atlas of human lung aging identifies cell type dyssynchrony and increased transcriptional entropy. Nature Communications 2026, 17: 2095. PMID: 41571679, PMCID: PMC12953888, DOI: 10.1038/s41467-026-68810-9.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsGenomic landscapeLung ageSingle-cell atlasAlveolar epithelialIndependent predictorsAnalysis of somatic mutationsSingle-cell dataSingle-cell RNA sequencingEndothelial cellsLoss of differentiationAlveolar epithelial cellsRNA sequencingTranscriptional changesCell-typeEndothelial cell typesSomatic mutationsMutational burdenAT2 cellsLung diseaseCell typesAge-related changesEpithelial cellsRisk factorsSenescence signatureEpithelial
2025
Long-term safety and efficacy outcomes of the Acellular Tissue Engineered Vessel (ATEV) in extremity arterial trauma repair
Curi M, Moore E, Namias N, Kundi R, Lum Y, Fox C, Goldin I, Bou-Ghannam S, Berdugo M, Khondker Z, Parikh S, Niklason L. Long-term safety and efficacy outcomes of the Acellular Tissue Engineered Vessel (ATEV) in extremity arterial trauma repair. Journal Of Vascular Surgery Cases And Innovative Techniques 2025, 12: 102042. PMID: 41438419, PMCID: PMC12720075, DOI: 10.1016/j.jvscit.2025.102042.Peer-Reviewed Original ResearchCitationsConceptsLong-term safetyAdverse eventsLimb salvageArterial injuryVascular injuryHigh-risk trauma populationArterial reconstructionSaphenous veinAutologous veinInfection-free rateCases of arterial injuryImmune-mediated rejectionKaplan-Meier methodSerious adverse eventsAssociated with lower infection ratesInfection rateLong-term patencyLimb salvage outcomesMechanism of injuryExtremity vascular injuriesSecondary patencyPrimary patencyPatient yearsEfficacy outcomesPatient survival
Academic Achievements & Community Involvement
Copy Link
Activities
activity Stem Cell Research
01/01/2007 - PresentResearchDetailsUnited KingdomAbstract/SynopsisProfessor Niklason collaborates with Dr. Sanjay Sinha and Dr. Roger Pedersen of Cambridge University. Their work centers on stem cell research.
Get In Touch
Copy Link